SOURCE: Leerink Swann & Company

July 13, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of AstraZeneca PLC (NYSE: AZN)

BOSTON, MA -- (MARKET WIRE) -- July 13, 2005 -- Yesterday after the close, Senior Large Cap Pharmaceutical Analyst, Andrew Oh, initiated coverage of AstraZeneca PLC with an Outperform rating. His investment rating is based on his belief that AstraZeneca's current valuation offers an attractive entry point for a company with top-tier EPS growth prospects and limited risk from generic drugs.

About AstraZeneca PLC

AstraZeneca PLC (NYSE: AZN) is one of the world's leading pharmaceutical companies. Its 2004 sales totaled $21.4 billion. AstraZeneca's broad portfolio of medicines includes many world leaders such as Nexium for gastrointestinal disease and Crestor for high cholesterol. It is working on a range of high-potential therapies for treating cancer, cardiovascular and gastrointestinal disease, infection, and neuroscience and respiratory problems. AstraZeneca is headquartered in London, UK.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564